172 related articles for article (PubMed ID: 8266767)
1. Current status on chromogranin A and pancreastatin.
Robberecht P; Lingier P; Woussen-Colle MC
Acta Gastroenterol Belg; 1993; 56(3-4):261-3. PubMed ID: 8266767
[TBL] [Abstract][Full Text] [Related]
2. Autocrine regulation of parathyroid secretion: inhibition of secretion by chromogranin-A (secretory protein-I) and potentiation of secretion by chromogranin-A and pancreastatin antibodies.
Fasciotto BH; Gorr SU; Bourdeau AM; Cohn DV
Endocrinology; 1990 Sep; 127(3):1329-35. PubMed ID: 2387256
[TBL] [Abstract][Full Text] [Related]
3. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.
Stridsberg M; Oberg K; Li Q; Engström U; Lundqvist G
J Endocrinol; 1995 Jan; 144(1):49-59. PubMed ID: 7891024
[TBL] [Abstract][Full Text] [Related]
4. Pancreastatin, a presumed product of chromogranin-A (secretory protein-I) processing, inhibits secretion from porcine parathyroid cells in culture.
Fasciotto BH; Gorr SU; DeFranco DJ; Levine MA; Cohn DV
Endocrinology; 1989 Sep; 125(3):1617-22. PubMed ID: 2759035
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A(210-301) is the major form of pancreastatin-like material in human gut extracts and endocrine tumors.
Woussen-Colle MC; Lingier P; Vertongen P; Vandermeers-Piret MC; Vandermeers A; Robberecht P
Peptides; 1994; 15(5):869-74. PubMed ID: 7984507
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A: a novel regulator of parathyroid gland secretion.
Cohn DV; Fasciotto BH; Reese BK; Zhang JX
J Nutr; 1995 Jul; 125(7 Suppl):2015S-2019S. PubMed ID: 7602385
[TBL] [Abstract][Full Text] [Related]
7. Effects of pancreastatin and chromogranin A on insulin release stimulated by various insulinotropic agents.
Ishizuka J; Tatemoto K; Cohn DV; Thompson JC; Greeley GH
Regul Pept; 1991 Jun; 34(1):25-32. PubMed ID: 1857778
[TBL] [Abstract][Full Text] [Related]
8. Pancreastatin--a novel regulatory peptide?
Schmidt WE; Creutzfeldt W
Acta Oncol; 1991; 30(4):441-9. PubMed ID: 1854501
[TBL] [Abstract][Full Text] [Related]
9. Pancreastatin, a chromogranin A-derived peptide, inhibits transcription of the parathyroid hormone and chromogranin A genes and decreases the stability of the respective messenger ribonucleic acids in parathyroid cells in culture.
Zhang JX; Fasciotto BH; Darling DS; Cohn DV
Endocrinology; 1994 Mar; 134(3):1310-6. PubMed ID: 8119171
[TBL] [Abstract][Full Text] [Related]
10. Pancreastatin and bovine parathyroid cell secretion.
Drees BM; Hamilton JW
Bone Miner; 1992 Jun; 17(3):335-46. PubMed ID: 1623328
[TBL] [Abstract][Full Text] [Related]
11. Pancreastatin: further evidence for its consideration as a regulatory peptide.
Sánchez-Margalet V; Lucas M; Goberna R
J Mol Endocrinol; 1996 Feb; 16(1):1-8. PubMed ID: 8672228
[TBL] [Abstract][Full Text] [Related]
12. Pancreastatin inhibits insulin secretion and stimulates glucagon secretion in mice.
Ahrén B; Lindskog S; Tatemoto K; Efendić S
Diabetes; 1988 Mar; 37(3):281-5. PubMed ID: 3286328
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of chromogranin A-derived peptides in bovine gut, pancreas and adrenal medulla.
Watkinson A; Jönsson AC; Davison M; Young J; Lee CM; Moore S; Dockray GJ
Biochem J; 1991 Jun; 276 ( Pt 2)(Pt 2):471-9. PubMed ID: 1710890
[TBL] [Abstract][Full Text] [Related]
14. The role of pancreatic chromogranins in islet physiology.
Karlsson E
Curr Mol Med; 2001 Dec; 1(6):727-32. PubMed ID: 11899258
[TBL] [Abstract][Full Text] [Related]
15. [Effect of pancreastatin on insulin secretion and the exocrine pancreas in rats].
von Schönfeld J; Müller MK; Neisius I; Geling M; Rünzi M; Goebell H
Z Gastroenterol; 1991 Oct; 29(10):523-6. PubMed ID: 1781189
[TBL] [Abstract][Full Text] [Related]
16. Pancreastatin: molecular and immunocytochemical characterization of a novel peptide in porcine and human tissues.
Schmidt WE; Siegel EG; Lamberts R; Gallwitz B; Creutzfeldt W
Endocrinology; 1988 Sep; 123(3):1395-404. PubMed ID: 3042370
[TBL] [Abstract][Full Text] [Related]
17. Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin.
Sánchez-Margalet V; González-Yanes C; Najib S; Santos-Alvarez J
Regul Pept; 2010 Apr; 161(1-3):8-14. PubMed ID: 20184923
[TBL] [Abstract][Full Text] [Related]
18. The occurrence of pancreastatin in tumours of the diffuse neuroendocrine system.
Bishop AE; Bretherton-Watt D; Hamid QA; Fahey M; Shepherd N; Valentino K; Tatemoto K; Ghatei MA; Bloom SR; Polak JM
Mol Cell Probes; 1988 Sep; 2(3):225-35. PubMed ID: 2851738
[TBL] [Abstract][Full Text] [Related]
19. Comparison of plasma pancreastatin and GAWK concentrations, presumed processing products of chromogranin A and B, in plasma of patients with pancreatic islet cell tumors.
Yasuda D; Iguchi H; Funakoshi A; Wakasugi H; Sekiya K; Misawa T; Tateishi K; Bloom SR; Nawata H
Horm Metab Res; 1993 Nov; 25(11):593-5. PubMed ID: 8288164
[TBL] [Abstract][Full Text] [Related]
20. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients.
Syversen U; Mignon M; Bonfils S; Kristensen A; Waldum HL
Acta Oncol; 1993; 32(2):161-5. PubMed ID: 8323758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
